OakChart

Jasper Therapeutics Inc

JSPRHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:58 PM ET

14.76+0.01 (0.07%)
2026-11-12 02:10 CET
Market cap
16.36 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-31.77 USD m
Free cash flow, TTM
-60.33 USD m
EPS diluted, TTM
-47.43
P/E
-
Compare

Price

JSPR against its 20, 50 and 200-day averages
2050200beat
20.0040.00498K997KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26JSPRclose 14.7620-day 15.2650-day 17.08200-day 24.3014.7652w low

79.7% under the 52-week high of 72.60 on 2 Dec 2025. 52-week low 9.45 on 29 Jun 2026. Last 15 sessions, 33.5% high to low

Volume 3.84× normal · the line is the 50-bar volume average

Profile

JSPR
52-week range, 8% of the way up
9.4572.60

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.

Employees22
IPOJan 10, 2020
Beta3.30
ATR, 14d1.92
Rel volume3.84
Inst own35.29%

Snapshot

6 groups

Valuation

Index-
Market Cap16.37M
Enterprise Value8.91M
Income-31.77M
Sales0.00M
Book/sh1.51
Cash/sh6.97
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees22
IPOJan 10, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B9.78
P/C2.12
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio1.47
Current Ratio1.47
Debt/Eq0.19
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-47.43
EPS next Y-15.50
EPS next Q-1.80
EPS this Y88.35%
EPS next Y-12.32%
EPS next 5Y48.38%
EPS past 3/5Y27.39% 48.97%
Sales past 3/5Y- -
EPS Y/Y TTM73.74%
Sales Y/Y TTM-
EPS Q/Q94.48%
Sales Q/Q-
EarningsAug 14 BMO
EPS/Sales Surpr.62.66% -

Ownership

Insider Own-
Insider Trans-
Inst Own35.29%
Inst Trans-
ROA-109.05%
ROE-255.05%
ROIC-2248.48%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-3.28%
SMA50-13.58%
SMA200-39.25%
Trades-

Technical

Shs Outstand0.94M
Shs Float-
Short Float-
Short Ratio12.64
Short Interest0.23M
52W High72.60 -79.67%
52W Low9.45 56.14%
Volatility17.84% 12.56%
ATR (14)1.92
RSI (14)44.43
Beta3.30
Rel Volume3.84
Avg Volume18.12K
Volume69,524

Performance

Perf Week-3.74%
Perf Month-0.73%
Perf Quarter-43.00%
Perf Half Y-46.53%
Perf YTD-73.11%
Perf Year-71.06%
Perf 3Y-92.87%
Perf 5Y-99.41%
Perf 10Y-
Recom1.00
Target Price270.00
Prev Close14.75
Price14.76
Change %0.07%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 14, 2026ResumedWWilliam BlairOutperform
Aug 12, 2026InitiatedPPiper SandlerOverweight$2-86.4%
May 15, 2026DowngradeTTD CowenBuy → Hold
Mar 23, 2026ResumedUUBSNeutral$1.50-89.8%
Jan 13, 2026InitiatedRRodman & RenshawBuy$17+15.2%
Jul 08, 2025DowngradeRRBC Capital MktsOutperform → Sector Perform$5-66.1%
Jul 08, 2025DowngradeBBMO Capital MarketsOutperform → Market Perform$4-72.9%
Jul 07, 2025DowngradeWWilliam BlairOutperform → Mkt Perform
Jul 07, 2025DowngradeCCantor FitzgeraldOverweight → Neutral
Feb 13, 2025InitiatedUUBSBuy$38+157.5%

Peers

Mkt cap
TickerCompanyMkt cap
COGTCogent Biosciences Inc5.12B
EVMNEvommune Inc312.84M
CNTBConnect Biopharma Holdings Ltd43.38M
UPBUpstream Bio Inc175.27M
ATTOAttovia Therapeutics Inc764.77M
ORKAOruka Therapeutics Inc7.27B
ANABAnaptysBio Inc1.46B
ALDXAldeyra Therapeutics Inc39.32M
ZURAZura Bio Ltd137.75M
JBIOJade Biosciences Inc1.05B

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • Jasper Therapeutics, Inc. Announces Results of the Offer to Purchase Relating to Its Warrants (GlobeNewswire)
  • Jasper Therapeutics Announces 1-for-30 Reverse Stock Split (GlobeNewswire) +6.48%
  • Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy (GlobeNewswire) +6.21%
  • Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants (GlobeNewswire)
  • Jasper Therapeutics Announces Key Regulatory and Clinical Appointments (GlobeNewswire) -9.91%
  • Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • Jasper Therapeutics beats Q2 expectations but shares fall after results (InvestorsHub) +6.59%
  • Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -8.46%
  • Jasper gets a lifeline in merger with immune drugmaker Kira (BioPharma Dive) +14.34%
  • Jasper Therapeutics Announces Merger with Kira Pharmaceuticals (GlobeNewswire) +11.85%
  • Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value (GlobeNewswire) -35.56%
  • Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -11.36%
  • Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -14.29%
  • Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-14-3.000-8.035-3.0000.000.004
2026Q12026-05-14-1.200-14.571-1.2290.000.005
2025Q42026-03-30-9.600-23.886-9.5250.000.006
2025Q32025-11-10-33.900-36.447-33.7880.000.007
2025Q22025-08-13-52.200-39.789-52.2820.000.009
2025Q12025-05-12-42.300-40.428-42.4190.000.009
2024Q42025-02-27-48.600-37.626-48.6140.000.0011
2024Q32024-11-07-37.200-32.139-37.2730.000.009
2024Q22024-08-13-29.100-32.658-29.1920.000.009
2024Q12024-05-14-30.900-36.750-30.8840.000.006
2023Q42024-03-04-45.000-48.261-45.0390.000.004
2023Q32023-11-09-48.000-46.560-47.9700.000.004
2023Q22023-08-11-45.000-44.541-44.1690.000.006
2023Q12023-05-12-48.000-48.690-48.5250.000.005
2022Q42023-03-08-108-112.2-108.130.000.005
2022Q32022-11-10-91.080-102-97.3290.000.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-807-673.31-806.680.000.00
2022FY-309-314.86-309.890.000.00
2023FY-185.4-184.85-185.260.000.00
2024FY-146.7-136.1-146.60.000.00
2025FY-118.5-131.41-128.320.000.00
2026FY--13.800--6.00
2027FY--15.500--0.00
2028FY--16.300--67.33
2029FY--24.800--3.61
2030FY--31.000--26.86

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-212006.000.0012.00
2026Q3S2026-10-132106.000.0012.00
2026Q3S2026-09-1611012.0012.0012.00
2026Q3S2026-09-152106.000.0012.00
2026Q3S2026-08-2311012.0012.0012.00
2026Q3S2026-08-142106.000.0012.00
2026Q3S2026-07-161000.000.000.00
2026Q3S2026-07-092000.000.000.00
2026Q3S2026-06-173000.000.000.00
2026Q3S2026-05-154000.000.000.00
2026Q3S2026-03-314000.000.000.00
2026Q3S2025-11-112000.000.000.00
2026Q3S2025-11-102000.000.000.00
2026Q3S2025-11-091000.000.000.00

Estimate history

EPS, annual-3428.988-806.679-309.885-185.262-146.595-118.636-47.4267
Period202020212022202320242025TTM
EPS, quarterly-29.192-37.273-48.614-42.419-52.282-33.788-9.525-1.229-2.885
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000
Period202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0090.1260.1270.3720.5010.9330.936
Period202020212022202320242025MRQ
Shares, quarterly0.5040.50.5010.5010.5410.9330.9330.9330.936
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue0.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.561.061.371.111.310.570.02
Gross Profit-0.56-1.06-1.37-1.11-1.31-0.57-0.02
Selling, General and Administrative Excl. Other51.2479.4676.3669.3851.7237.3620.96
Research and Development34.1160.5257.3153.4136.4626.5216.18
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income-51.80-80.52-77.73-70.49-53.03-37.93-20.98
Interest Expense0.000.000.000.000.000.000.00
Unusual Expense-18.78-5.160.000.56-12.93-6.2810.88
Net Income Before Taxes-31.77-75.80-72.76-66.09-39.52-31.73-31.97
Income Taxes0.000.00-1.49-1.63-1.83-1.09-0.30
Consolidated Net Income-31.77-75.80-71.27-64.47-37.69-30.64-31.67
Net Income From Continuing Operations-31.77-75.80-71.27-64.47-37.69-30.64-31.67
Net Income-31.77-75.80-71.27-64.47-37.69-30.64-31.67
EPS (Recurring)-46.96-124.29-146.60-184.14-384.28-922.35-2,604.74
EPS (Basic, Before Extraordinaries)-47.43-118.64-146.59-185.26-309.88-806.68-3,428.99
EPS (Diluted)-47.43-118.64-146.59-185.26-309.88-806.68-3,428.99
EBITDA-51.24-79.46-76.36-69.38-51.72-37.36-20.96
Non-Operating Income (Expense)1.25-0.454.974.950.59-0.08-0.11
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense4.276.716.625.214.091.051.21
Shares Outstanding0.940.930.500.370.130.130.01
Market Capitalization16.3616.36321.1787.4618.34297.16317.66

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.020.020.290.230.260.280.240.54
Gross Profit-0.02-0.02-0.29-0.23-0.26-0.28-0.24-0.54
Selling, General and Administrative Excl. Other9.1910.9312.1818.9426.8221.5225.0419.35
Research and Development5.135.818.7714.3921.2016.1619.7714.46
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-9.21-10.95-12.47-19.17-27.08-21.80-25.29-19.89
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense-3.98-9.64-3.06-2.100.000.000.00-0.02
Net Income Before Taxes-2.76-1.17-9.10-18.74-26.72-21.24-24.32-18.64
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-2.76-1.17-9.10-18.74-26.72-21.24-24.32-18.64
Net Income From Continuing Operations-2.76-1.17-9.10-18.74-26.72-21.24-24.32-18.64
Net Income-2.76-1.17-9.10-18.74-26.72-21.24-24.32-18.64
EPS (Recurring)-5.80-8.29-11.77-36.44-52.28-42.42-48.61-37.30
EPS (Basic, Before Extraordinaries)-2.89-1.23-9.53-33.79-52.28-42.42-48.61-37.27
EPS (Diluted)-2.89-1.23-9.53-33.79-52.28-42.42-48.61-37.27
EBITDA-9.19-10.93-12.18-18.94-26.82-21.52-25.04-19.35
Non-Operating Income (Expense)2.470.140.31-1.670.350.560.961.23
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.760.421.661.421.821.811.972.00
Shares Outstanding0.940.930.930.930.540.500.500.50
Market Capitalization16.3624.5351.2366.6090.0264.60321.17282.18

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments28.6971.6486.8938.2584.7019.84
Short Term Receivables0.000.000.251.160.700.60
Inventories0.000.000.000.000.000.00
Other Current Assets5.954.171.802.322.430.25
Total Current Assets34.6575.8188.9441.7387.8320.68
Net Property, Plant & Equipment0.602.854.195.454.832.03
Total Investments and Advances0.420.420.420.420.340.34
Intangible Assets-----0.00
Deferred Tax Assets--0.490.560.320.40
Other Assets0.110.821.340.760.650.30
Total Assets35.7879.9095.3848.9293.9823.76
Short Term Debt Incl. Current Port. of LT Debt1.241.090.970.860.510.00
Accounts Payable6.224.034.151.773.921.42
Income Tax Payable-----0.00
Other Current Liabilities5.7510.127.254.433.602.60
Total Current Liabilities13.2015.2412.377.078.024.01
Long Term Debt0.000.721.812.792.381.62
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--0.490.560.320.40
Other Liabilities16.160.000.000.2613.148.41
Total Liabilities29.3615.9614.6810.6723.8614.45
Non-Equity Reserves2.262.262.262.260.600.60
Preferred Stock - Carrying Value0.000.000.000.000.0043.84
Common Equity4.1561.6778.4435.9969.52-35.13
Total Shareholders Equity4.1561.6778.4435.9969.528.71
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity4.1561.6778.4435.9969.528.71
Total Liabilities & Stockholders Equity35.7879.9095.3848.9293.9823.76
Book Value Per Share4.45123.17210.79283.78550.93-3,803.73
Tangible Book Value Per Share4.45123.17210.79283.78550.93-3,803.73
Full-Time Employees22644535253
Price to Book Ratio9.775.210.930.394.274.04
Return on Assets-131.06-81.32-89.35-52.74-31.38-
Return on Equity-230.31-101.73-112.67-71.44-39.82-
Return on Invested Capital-1,826.09-114.22-80.33-97.19-42.61-306.45
Quick Ratio2.624.987.195.9110.955.16
Current Ratio2.624.987.195.9110.955.16

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-31.77-75.80-71.27-64.47-37.69-30.64-31.67
Depreciation0.561.061.371.111.310.570.02
Other Funds (Non Cash)-16.032.517.126.19-8.83-5.2312.09
Funds from Operations-47.24-72.24-62.77-57.17-45.21-35.30-19.56
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital-13.09-4.920.175.10-0.651.621.30
Income Taxes Payable-------0.02
Cash from Operating Activities-60.33-77.16-62.60-52.07-45.86-33.68-18.27
Capital Expenditures0.00-0.01-0.55-0.27-0.58-2.430.00
Net Assets From Acquisitions0.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.080.010.020.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.00
Cash from Investing Activities0.080.01-0.53-0.27-0.58-2.430.00
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock28.0634.2147.88101.930.06100.9711.29
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00
Sale of Common Pref Stock28.0634.2147.88101.930.06100.9711.29
Proceedsfrom Stock Options0.546.7047.20101.480.03100.7311.23
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-0.960.000.000.00
Other Financing Activities Uses0.000.000.00-0.960.000.000.00
Cash from Financing Activities28.0634.2147.88100.970.06100.9711.29
Net Change in Cash-32.20-42.95-15.2548.64-46.3864.86-6.98
Free Cash Flow-60.33-77.17-63.15-52.33-46.43-36.11-18.27
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments7.7314.1428.6950.9039.5148.80
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets3.846.155.953.673.464.38
Total Current Assets11.5720.2934.6554.5642.9753.17
Net Property, Plant & Equipment0.190.400.602.342.893.47
Total Investments and Advances0.000.420.420.420.420.42
Other Assets0.040.080.110.150.190.53
Total Assets11.8021.1835.7857.4746.4757.60
Short Term Debt Incl. Current Port. of LT Debt0.270.761.241.701.951.83
Accounts Payable2.782.446.229.178.033.00
Other Current Liabilities4.805.805.7510.1710.517.50
Total Current Liabilities7.849.0013.2021.0420.5012.33
Long Term Debt0.000.000.000.000.200.76
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities2.546.5216.1622.590.000.00
Total Liabilities10.3915.5229.3643.6320.7013.09
Non-Equity Reserves0.002.262.262.262.262.26
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1.413.404.1511.5723.5042.24
Total Shareholders Equity1.413.404.1511.5723.5042.24
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1.413.404.1511.5723.5042.24
Total Liabilities & Stockholders Equity11.8021.1835.7857.4746.4757.60
Book Value Per Share1.513.644.4512.4043.4784.36
Tangible Book Value Per Share1.513.644.4512.4043.4784.36
Full-Time Employees25-22-4360
Price to Book Ratio9.777.2112.345.763.831.53
Return on Assets-109.05-141.49-131.06-116.04-113.37-85.84
Return on Equity-255.05-244.21-230.31-191.12-146.87-101.34
Return on Invested Capital-195.33-34.53-219.25-161.92-112.75-49.40
Quick Ratio1.472.262.622.592.104.31
Current Ratio1.472.262.622.592.104.31

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-2.76-1.17-9.10-18.74-26.72-21.24
Depreciation0.020.020.290.230.260.28
Other Funds (Non Cash)-5.37-9.03-3.331.702.132.00
Funds from Operations-8.11-10.19-12.14-16.81-24.33-18.96
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.19-4.36-9.73-0.198.88-3.88
Cash from Operating Activities-6.92-14.55-21.87-17.00-15.45-22.84
Capital Expenditures0.000.000.000.00-0.010.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.080.000.000.000.010.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.080.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.010.00-0.3428.396.160.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.010.00-0.3428.396.160.00
Proceedsfrom Stock Options0.010.000.240.296.160.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.010.00-0.3428.396.160.00
Net Change in Cash-6.83-14.55-22.2111.39-9.29-22.84
Free Cash Flow-6.92-14.55-21.87-17.00-15.46-22.84

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-30-0.2M-16.56K
2026-10-1521.71%0.2M1.0M42.54K
2026-09-3020.85%0.2M1.0M45.75K
2026-09-1519.48%0.2M1.0M47.42K
2026-08-3118.82%0.2M1.0M50.35K
2026-08-1418.29%0.2M1.0M48.41K
2026-07-3117.43%0.1M0.8M45.77K
2026-07-156.59%0.1M0.8M18.61K
2026-06-306.76%0.1M0.8M18.41K
2026-06-157.77%0.1M0.8M16.75K
2026-05-299.26%0.1M0.8M13.60K
2026-05-1510.25%0.1M0.8M13.83K
2026-04-3011.26%0.1M0.8M15.66K
2026-04-1511.30%0.1M0.8M16.52K
2026-03-3112.48%0.1M0.8M19.98K
2026-03-1312.92%0.1M0.8M22.36K
2026-02-2713.83%0.1M0.8M58.62K
2026-02-1314.22%0.1M0.8M59.14K
2026-01-3014.73%0.1M0.8M58.47K
2026-01-1515.27%0.1M0.8M57.12K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.000.000.05-1010.00---
call1.000.000.000.00-0.000.00---
call1.500.000.000.00-0.000.00---
call2.000.000.000.00-0.000.00---
call2.500.000.000.00-0.000.00---
call5.000.000.000.00-0.000.00---
call7.500.000.000.00-0.000.00---
put0.500.000.000.00-0.000.00---
put1.000.000.000.00-0.000.00---
put1.500.000.000.00-0.000.00---
put2.000.000.000.00-0.000.00---
put2.500.000.002.10-0.000.00---
put5.000.000.000.00-0.000.00---
put7.500.000.007.10-0.000.00---

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-098-KCurrent report2026-11-07SEC
2026-11-048-KCurrent report2026-11-02SEC
2026-10-28SCHEDULE 13GSEC
2026-10-23SC TO-I/ASEC
2026-10-19DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-13SEC
2026-10-158-KCurrent report2026-10-15SEC
2026-10-14S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-10-09PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-09SEC
2026-10-078-KCurrent report2026-10-07SEC
2026-10-07SC TO-IIssuer tender offer statementSEC
2026-10-058-KCurrent report2026-09-30SEC
2026-10-058-K/A2026-07-16SEC
2026-10-018-K/A2026-07-16SEC
2026-09-288-KCurrent report2026-09-23SEC
2026-09-2425-NSESEC
2026-09-04DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-30SEC
2026-08-268-KCurrent report2026-08-21SEC
2026-08-24PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-08-24SEC
2026-08-17SCHEDULE 13GSEC
2026-08-148-KCurrent report2026-08-14SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-05DNotice of sales of securities on Form D (Regulation D)SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-08-038-KCurrent report2026-07-31SEC
2026-07-318-KCurrent report2026-07-31SEC
2026-07-233Initial statement of beneficial ownership of securities2026-07-16SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Velan Capital Investment Management LP9.53%
ACORN CAPITAL ADVISORS, LLC5.13%
KINGDON CAPITAL MANAGEMENT, L.L.C.4.83%
VANGUARD CAPITAL MANAGEMENT LLC4.18%
Rock Springs Capital Management LP3.93%
Carlyle Group Inc.3.20%
GSA CAPITAL PARTNERS LLP1.91%
MILLENNIUM MANAGEMENT LLC1.74%
Lion Point Capital, LP1.66%
GEODE CAPITAL MANAGEMENT, LLC0.90%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.98%
VANGUARD EXTENDED MARKET INDEX FUND1.11%
Fidelity Extended Market Index Fund0.49%
Fidelity Total Market Index Fund0.15%
Fidelity Series Total Market Index Fund0.10%
VANGUARD BALANCED INDEX FUND0.09%
Fidelity Nasdaq Composite Index Fund0.03%
Knights of Columbus U.S. ALL CAP INDEX FUND0.00%
Blackstone Alternative Multi-Strategy Fund-0.01%

OakChart. JSPR. Cached 15 minutes.

Some panels did not load: insider.